Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Beyerlin K, Jimenez R, Zangardi M, Fell GG, Edmonds C, Johnson A, Bossuyt V, Specht M, Mulvey TM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Spring LM. Beyerlin K, et al. Among authors: fell gg. J Oncol Pharm Pract. 2020 Nov 5:1078155220971751. doi: 10.1177/1078155220971751. Online ahead of print. J Oncol Pharm Pract. 2020. PMID: 33153384
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.
Daniels VW, Zoeller JJ, van Gastel N, McQueeney KE, Parvin S, Potter DS, Fell GG, Ferreira VG, Yilma B, Gupta R, Spetz J, Bhola PD, Endress JE, Harris IS, Carrilho E, Sarosiek KA, Scadden DT, Brugge JS, Letai A. Daniels VW, et al. Among authors: fell gg. Sci Signal. 2021 Jun 8;14(686):eabc7405. doi: 10.1126/scisignal.abc7405. Sci Signal. 2021. PMID: 34103421